BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36924334)

  • 21. The landscape of new drugs in extranodal NK/T-cell lymphoma.
    Wang L; Li LR; Zhang L; Wang JW
    Cancer Treat Rev; 2020 Sep; 89():102065. PubMed ID: 32653806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
    Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
    Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients.
    Li K; Wang R; Huang S; Pan X; Chen H; Zhou L; Wei J; Wu C; Zhu X; Liang S; Qu S
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e537-e543. PubMed ID: 30243570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.
    Kim SJ; Yoon DH; Jaccard A; Chng WJ; Lim ST; Hong H; Park Y; Chang KM; Maeda Y; Ishida F; Shin DY; Kim JS; Jeong SH; Yang DH; Jo JC; Lee GW; Choi CW; Lee WS; Chen TY; Kim K; Jung SH; Murayama T; Oki Y; Advani R; d'Amore F; Schmitz N; Suh C; Suzuki R; Kwong YL; Lin TY; Kim WS
    Lancet Oncol; 2016 Mar; 17(3):389-400. PubMed ID: 26873565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of the systemic immune-inflammation index in patients with extranodal natural killer/T-cell lymphoma.
    Hai T; Wu W; Ren K; Li N; Zou L
    Front Oncol; 2023; 13():1273504. PubMed ID: 37909016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma.
    Wang Y; Xie L; Tian R; Deng Y; Zhang W; Zou L; Zhang H; Liu J; Zhao S; Ding W; Liu W; Jiang M
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2529-2539. PubMed ID: 31485768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study.
    Qi SN; Yang Y; Zhang YJ; Huang HQ; Wang Y; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Yuan ZY; Su H; Song YQ; Zhu J; Hu C; Li YX
    Am J Hematol; 2020 Sep; 95(9):1047-1056. PubMed ID: 32449800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
    Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
    Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Outcome of radiotherapy for low-risk early-stage patients with extranodal NK/T-cell lymphoma, nasal-type].
    Wang XD; Liu X; Wu T; Yang Y; Qi SN; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Zhu SY; Shi M; Su H; Zhang XM; Zhang HL; Huang HQ; Zhang YJ; Song YQ; Zhu J; Wang Y; Li YX
    Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1105-1113. PubMed ID: 34695903
    [No Abstract]   [Full Text] [Related]  

  • 30. Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy.
    Li YY; Feng LL; Niu SQ; Wang HY; Zhang LL; Wang L; Xia ZJ; Huang HQ; Xia YF; Zhang YJ; Wang XC
    Oncotarget; 2017 Feb; 8(7):11480-11488. PubMed ID: 28002792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/T cell lymphoma.
    Wang L; Xia ZJ; Lu Y; Wang QX; Niu SQ; Huang HQ; Zhang YJ
    Leuk Lymphoma; 2015; 56(11):3038-44. PubMed ID: 25747971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effects of sequence of radiotherapy and chemotherapy on prognosis of patients with early-stage extranodal NK/T cell lymphoma (nasal type) and its individualized application].
    Yang J; Yang Y; Qi SN; Wu T; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Zhu SY; Shi M; Su H; Zhang XM; Zhang HL; Huang HQ; Zhang YJ; Song YQ; Zhu J; Wang Y; Li YX
    Zhonghua Yi Xue Za Zhi; 2021 May; 101(17):1232-1238. PubMed ID: 34865391
    [No Abstract]   [Full Text] [Related]  

  • 33. A five
    Vittayawacharin P; Khuhapinant A
    Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of extranodal NK/T-cell lymphoma: From past to future.
    Yan Z; Yao S; Wang Z; Zhou W; Yao Z; Liu Y
    Front Immunol; 2023; 14():1088685. PubMed ID: 36825002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics and survival of extranodal natural killer/T-cell lymphoma: a single-center 12-year retrospective analysis.
    Chen Y; Luo L; Zheng X; Fu H; Yang X; Huang W; Chen L; Zheng Z; Zheng J; Yang T; Liu T; Hu J
    Leuk Lymphoma; 2020 Dec; 61(14):3306-3318. PubMed ID: 32820684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NK- and T-cell lymphoma of the nasal cavity and paranasal sinuses in Denmark 1980-2017: a nationwide cohort study.
    Eriksen PRG; Clasen-Linde E; Brown PN; Haunstrup L; Christoffersen M; Asdahl P; Thomsen TM; von Buchwald C; Heegaard S
    Leuk Lymphoma; 2022 Nov; 63(11):2579-2588. PubMed ID: 35699970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma.
    Qi F; Xie Y; Wang D; Chai Y; Chen B; Sun Y; Liu W; Qi S; Wei Y; Fang H; Zhao D; Gui L; Yang Y; Feng X; Ding N; Mi L; Shu S; Li Y; Song Y; Dong M; Zhu J
    Ann Hematol; 2022 Sep; 101(9):2021-2034. PubMed ID: 35798977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma].
    Wu T; Liu QL; Hu YF; Zhang J; Chen MX; Chen XX; Huang YH; Lu B
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):859-864. PubMed ID: 31770855
    [No Abstract]   [Full Text] [Related]  

  • 39. A novel prognostic model for extranodal natural killer/T-cell lymphoma.
    Huang JJ; Zhu YJ; Xia Y; Zhao W; Lin TY; Jiang WQ; Huang HQ; Li ZM
    Med Oncol; 2012 Sep; 29(3):2183-90. PubMed ID: 21786011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic evaluation of the prognostic value of
    Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
    Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.